European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS

Preparing for RSV Immunisation and Surveillance in Europe

Projektbeschreibung

DE EN ES FR IT PL

Integrierte Forschung zu RSV-Impfungen

Das hochansteckende Respiratorische Synzytial-Virus (RSV) verursacht Lungen- und Atemwegsinfektionen. RSV-Infektionen treten saisonal auf und reichen von grippeähnlicher Symptomatik bis hin zu schweren Atemwegserkrankungen vor allem bei kleinen Kindern und älteren Menschen. Um lebensbedrohliche Komplikationen zu vermeiden, besteht dringende Notwendigkeit, einen RSV-Impfstoff in nationale Impfprogramme aufzunehmen. Das EU-finanzierte Projekt PROMISE trägt in epidemiologischen Analysen Daten aus nationalen Registern und systematischen Auswertungen zusammen und validiert neue Biomarker für RSV-Infektionen. Ein EU-weites RSV-Überwachungssystem, das Monitoring nach der Markteinführung und weitere klinische Prüfungen von RSV-Impfstoffen sollen deren Sicherheit und Wirksamkeit gewährleisten.

Ziel

RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progress has been made in development of products for active and passive immunization against RSV, with 19 products currently in clinical development. In 2017, we were funded by IMI to set up RESCEU project (Grant Agreement number 116019), which is the single largest consortium currently working on RSV and has addressed several of the key evidence gaps to inform the introduction of an RSV vaccine. However, new gaps in evidence have emerged and many key requirements for the introduction of a novel RSV vaccine into national immunisation programmes (not addressed within RESCEU) remain unmet. PROMISE’s vision is to seamlessly build on, exploit, and add value to the significant achievements of RESCEU to prepare for the imminent introduction of an RSV vaccine. Expanding the existing RESCEU network to include 5 new partners, PROMISE comprises of 5 distinct but inter-connected work packages (WPs). WP 1 will conduct epidemiological and cost-effectiveness analyses marshalling data from systematic reviews; national and regional disease registries; surveillance programmes and linked routine healthcare datasets. WP2 will foster a consensus and develop an operational plan for expanded coordinated RSV surveillance and reporting activities; post-licensure monitoring and evaluation of products for RSV immunization across Europe. WP3 will initiate new prospective studies to address key gaps in existing knowledge (RSV disease severity scores, asthma in school age children) and assemble biobanks for biomarker validation. WP4 will validate temporally and at mucosal level biomarkers that were identified in RESCEU adopting state of the art technologies. WPs 1-4 will develop high-quality, sustainable, robust data collection systems that link closely with public health/regulatory bodies/health care providers for informing policy and regulatory processes.

Wissenschaftliches Gebiet

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

H2020-JTI-IMI2-2020-22-single-stage

Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

RIA - Research and Innovation action

Koordinator

THE UNIVERSITY OF EDINBURGH
Netto-EU-Beitrag
€ 746 625,00
Adresse
OLD COLLEGE, SOUTH BRIDGE
EH8 9YL Edinburgh
Vereinigtes Königreich

Auf der Karte ansehen
Region
Scotland Eastern Scotland Edinburgh
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 746 625,00

Beteiligte (22)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 29 April 2024

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/101034339/de

European Union, 2024